- Home
- LVS vs TAK Comparison
LVS vs TAK Comparison
Compare LVS & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVS
- TAK
- Stock Information
- Founded
- LVS 1988
- TAK 1781
- Country
- LVS United States
- TAK Japan
- Employees
- LVS N/A
- TAK N/A
- Industry
- LVS Hotels/Resorts
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- LVS Consumer Discretionary
- TAK Health Care
- Exchange
- LVS Nasdaq
- TAK Nasdaq
- Market Cap
- LVS 39.5B
- TAK 47.3B
- IPO Year
- LVS 2004
- TAK N/A
- Fundamental
- Price
- LVS $58.20
- TAK $14.10
- Analyst Decision
- LVS Buy
- TAK
- Analyst Count
- LVS 13
- TAK 0
- Target Price
- LVS $64.46
- TAK N/A
- AVG Volume (30 Days)
- LVS 6.2M
- TAK 2.8M
- Earning Date
- LVS 10-22-2025
- TAK 10-30-2025
- Dividend Yield
- LVS 1.72%
- TAK 3.85%
- EPS Growth
- LVS 9.73
- TAK N/A
- EPS
- LVS 2.22
- TAK 0.59
- Revenue
- LVS $12,264,000,000.00
- TAK $31,053,301,865.00
- Revenue This Year
- LVS $9.22
- TAK $0.14
- Revenue Next Year
- LVS $4.97
- TAK $0.58
- P/E Ratio
- LVS $26.27
- TAK $46.53
- Revenue Growth
- LVS 8.37
- TAK 1.52
- 52 Week Low
- LVS $30.18
- TAK $12.80
- 52 Week High
- LVS $59.66
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- LVS 64.49
- TAK 42.50
- Support Level
- LVS $49.20
- TAK $13.99
- Resistance Level
- LVS $59.66
- TAK $14.23
- Average True Range (ATR)
- LVS 1.93
- TAK 0.12
- MACD
- LVS 1.14
- TAK 0.04
- Stochastic Oscillator
- LVS 89.38
- TAK 74.14
About LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, the company generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.